Get the Stockscreener App
11.49
1.37%
-0.16
After Hours:
11.99
0.50
+4.35%
Ars Pharmaceuticals Inc stock is traded at $11.49, with a volume of 1.68M.
It is down -1.37% in the last 24 hours and up +27.10% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$11.65
Open:
$11.65
24h Volume:
1.68M
Relative Volume:
0.81
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-24.45
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
+0.97%
1M Performance:
+27.10%
6M Performance:
-31.40%
1Y Performance:
+7.28%
1-Day Range:
$11.43
$11.75
1-Week Range:
$11.31
$11.99
52-Week Range:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.49 | 1.15B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
The Technical Signals Behind (SPRY) That Institutions Follow - Stock Traders Daily
ARS Pharmaceuticals Stock Pre-Market (+4.4%) : 'neffy' Nasal Spray Approved in China - Trefis
Is ARS Pharmaceuticals a buy? - Cantech Letter
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg - Yahoo Finance
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - simplywall.st
China approves first community use epinephrine nasal spray for allergies By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 3.4%Time to Buy? - MarketBeat
ARS Pharma Receives Approval For Neffy In China, Expanding Global Reach - Nasdaq
ARS Pharmaceuticals Wins China Approval for First Community-Use Epinephrine for Allergic Reactions - marketscreener.com
ARS Pharmaceuticals' neffy Approved as First Epinephrine Nasal Spray for Out-of-Hospital Use in China - Quiver Quantitative
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - The Manila Times
Needle-free allergy rescue spray cleared in China for home use - Stock Titan
ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Trading Systems Reacting to (SPRY) Volatility - Stock Traders Daily
Is ARS Pharmaceuticals Inc. stock cheap at current valuationJuly 2025 Highlights & Reliable Volume Spike Alerts - Улправда
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 7.9% HigherWhat's Next? - MarketBeat
Can ARS Pharmaceuticals Inc. stock hit record highs againJuly 2025 Setups & Verified Trade Idea Suggestions - Bölüm Sonu Canavarı
What insider trading reveals about ARS Pharmaceuticals Inc. stockMarket Performance Report & Daily Stock Trend Watchlist - Улправда
Is ARS Pharmaceuticals Inc. stock near bottom after declineMarket Sentiment Summary & High Conviction Investment Ideas - ulpravda.ru
ARS Pharmaceuticals Earnings Notes - Trefis
Avoiding Lag: Real-Time Signals in (SPRY) Movement - news.stocktradersdaily.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 6.3%Time to Buy? - MarketBeat
Is ARS Pharmaceuticals Inc a good long term investmentStock Correlation Metrics & Investment Recommendations You Can Trust - earlytimes.in
Next Century Growth Investors LLC Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Ardsley Advisory Partners LP Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How ARS Pharmaceuticals Inc. stock reacts to global recession fearsJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - Newser
Why ARS Pharmaceuticals Inc. stock is favored by pension fundsPortfolio Update Report & Safe Capital Investment Plans - Newser
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8.1%Here's What Happened - MarketBeat
Is ARS Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 Momentum & Short-Term Swing Trade Alerts - Newser
Discipline and Rules-Based Execution in SPRY Response - news.stocktradersdaily.com
ARS Pharmaceuticals, Inc. $SPRY Shares Bought by Geode Capital Management LLC - MarketBeat
How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts - Yahoo Finance
Steward Partners Investment Advisory LLC Raises Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Franklin Resources Inc. Sells 28,789 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes $1.77 Million Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
ARS Pharmaceuticals, Inc. to Participate in Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
ARS Pharmaceuticals (NASDAQ: SPRY) in fireside chat at Piper Sandler 37th Conference - Stock Titan
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
ARS Pharmaceuticals (NASDAQ:SPRY) Raised to Hold at Zacks Research - MarketBeat
Behavioral Patterns of SPRY and Institutional Flows - news.stocktradersdaily.com
Is ARS Pharmaceuticals Inc. stock supported by strong fundamentals2025 Key Highlights & Precise Buy Zone Tips - newser.com
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
Will ARS Pharmaceuticals Inc. stock maintain momentum in 2025Earnings Overview Summary & Consistent Growth Stock Picks - newser.com
How ARS Pharmaceuticals Inc. stock benefits from strong dollarPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineQuarterly Growth Report & AI Powered Market Entry Ideas - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery play2025 Market Trends & Accurate Buy Signal Alerts - newser.com
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):